Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Zelira Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$7.38 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
11.35 million
Earnings per share
-3.236
Dividend per share
N/A
Year To Date Return
-22.22%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Zelira Therapeutics Ltd (ASX: ZLD)
Latest News
Healthcare Shares
Guess which obscure ASX healthcare share just exploded 220% on HUGE news
Cannabis Shares
Off and racing: Zelira shares fly 37% higher on Thursday
Share Gainers
Why has this ASX medicinal cannabis share soared 49% in two days?
Share Market News
Zelira shares rocket 28% before being placed on ice. Here's the latest.
Cannabis Shares
Blazing it? How the top ASX cannabis shares performed in FY21
Cannabis Shares
Why the Zelira (ASX:ZLD) share price is storming 7% higher
Cannabis Shares
Zelira (ASX:ZLD) share price falls despite strong trading update
Share Market News
What will Elite Cannabinoids mean for ASX cannabis shares?
Cannabis Shares
CBD to be sold in pharmacies, ASX cannabis shares react
Share Market News
The sector that'll grow 480% this year, expert says
Best Shares
5 top ASX cannabis shares in 2020
Share Market News
Here's why the Zelira (ASX:ZLD) share price just rocketed to a new high
ZLD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Zelira Therapeutics Ltd
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
ZLD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Nov 2024 | $0.65 | $-0.01 | -1.52% | 848 | $0.70 | $0.70 | $0.65 |
| 19 Nov 2024 | $0.66 | $0.00 | 0.00% | 1,086 | $0.66 | $0.66 | $0.66 |
| 18 Nov 2024 | $0.66 | $0.00 | 0.00% | 2,218 | $0.66 | $0.66 | $0.66 |
| 15 Nov 2024 | $0.66 | $-0.04 | -5.71% | 641 | $0.70 | $0.72 | $0.66 |
| 14 Nov 2024 | $0.70 | $0.00 | 0.00% | 471 | $0.70 | $0.70 | $0.70 |
| 13 Nov 2024 | $0.70 | $0.00 | 0.00% | 9 | $0.70 | $0.70 | $0.70 |
| 12 Nov 2024 | $0.70 | $0.04 | 6.06% | 544 | $0.66 | $0.70 | $0.66 |
| 11 Nov 2024 | $0.66 | $-0.04 | -5.71% | 3,703 | $0.70 | $0.70 | $0.66 |
| 08 Nov 2024 | $0.70 | $-0.05 | -6.67% | 2,567 | $0.75 | $0.75 | $0.70 |
| 07 Nov 2024 | $0.75 | $0.00 | 0.00% | 158 | $0.75 | $0.75 | $0.75 |
| 06 Nov 2024 | $0.75 | $0.01 | 1.35% | 2,042 | $0.74 | $0.78 | $0.74 |
| 05 Nov 2024 | $0.74 | $0.03 | 4.23% | 5,369 | $0.74 | $0.78 | $0.74 |
| 04 Nov 2024 | $0.71 | $0.01 | 1.43% | 4,939 | $0.67 | $0.71 | $0.66 |
| 31 Oct 2024 | $0.70 | $0.02 | 2.96% | 3,066 | $0.67 | $0.73 | $0.66 |
| 30 Oct 2024 | $0.68 | $-0.05 | -6.90% | 3,874 | $0.73 | $0.73 | $0.68 |
| 29 Oct 2024 | $0.73 | $-0.01 | -1.36% | 8,831 | $0.74 | $0.76 | $0.73 |
| 28 Oct 2024 | $0.74 | $-0.10 | -12.05% | 34,192 | $0.82 | $0.82 | $0.66 |
| 25 Oct 2024 | $0.83 | $-0.05 | -5.68% | 3,602 | $0.88 | $0.90 | $0.82 |
| 24 Oct 2024 | $0.88 | $-0.01 | -1.13% | 1,549 | $0.89 | $0.89 | $0.88 |
| 23 Oct 2024 | $0.89 | $0.01 | 1.14% | 1,018 | $0.88 | $0.89 | $0.88 |
| 22 Oct 2024 | $0.88 | $-0.03 | -3.30% | 1,866 | $0.92 | $0.92 | $0.88 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 24 Nov 2023 | Timothy (Tim) Slate | Issued | 100,000 | $47,335 |
Director remuneration.
|
| 24 Nov 2023 | Oludare Odumosu | Issued | 200,000 | $94,669 |
Director remuneration. As per announcement on 24-11-2023
|
| 24 Nov 2023 | Osagie Imasogie | Issued | 150,000 | $71,002 |
Director remuneration.
|
| 24 Nov 2023 | Greg Blake | Issued | 175,000 | $82,836 |
Director remuneration.
|
| 24 Nov 2023 | Donna O'Donnell | Issued | 145,000 | $91,430 |
Director remuneration.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Timothy (Tim) Ryan Slate | Company SecretaryNon-Executive Director | Dec 2016 |
Mr Slate provides accounting and secretarial advice to private and public companies. Mr Slate has over 15 years of experience in chartered accounting.
|
| Dr Oludare Odumosu | Managing Director | Dec 2019 |
Dr Odumosu has over 10 years of experience in corporate pharmaceutical business development, strategy & operational leadership including alliance management, Dr. Odumosu brings a unique combination of experiences from several academic, public health and life science organisations.
|
| Mr Osagie Imasogie | Non-Executive ChairmanNon-Executive Director | Dec 2019 |
Mr Imasogie has over 30 years of experience in the fields of law, finance, business management, healthcare and the pharmaceutical industry. He is a co-founder and the Senior Managing Partner of PIPV Capital, a Private Equity Firm that is focused on the Life Sciences vertical. Prior to co-founding PIPV Capital, Osagie conceptualised and established GlaxoSmithKline Ventures and was its founding Vice President.
|
| Mr Greg Blake | Executive Director | Feb 2023 |
Mr Blake has led the strategic development and commercialisation of a number of products across a range of therapeutic categories. Throughout his near 20 years working in healthcare Greg has built a solid foundation of knowledge across marketing and the entire commercial value chain.
|
| Dr Donna Gentile O'Donnell | Non-Executive Director | Jun 2023 |
Dr O'Donnell has led a diverse and successful career in health care, life sciences and public service concentrated in the Greater Philadelphia area. Donna was formerly a principal with O'Donnell Associates, her clients included non-profit organisations, universities, and life science companies, including Cephalon Pharmaceuticals.
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Malik Majeed | 1,134,644 | 10.00% |
| Quincy Street Capital Llc | 456,622 | 4.02% |
| Sharri J Rochlin <Rochlin Family Resource A/C> | 393,168 | 3.46% |
| Mr Zoltan Kerekes | 393,168 | 3.46% |
| Osagie Imasogie | 393,168 | 3.46% |
| Sunset Capital Management Pty Ltd <Sunset Superfund A/C> | 383,725 | 3.38% |
| Ms Lisa Gray | 381,988 | 3.37% |
| Mera I Llc\C | 332,479 | 2.93% |
| Muller Ct Pty Ltd <Muller Super Fund A/C> | 312,126 | 2.75% |
| Mr Torsten M Geers <The Torsten M Geers Living A/C> | 307,454 | 2.71% |
| Mr Steve Shapiro | 302,571 | 2.67% |
| Mara Gordon | 252,242 | 2.22% |
| Mr Saul Shorr and Mrs Margaret Shorr | 151,285 | 1.33% |
| Dr Chanda Latrice Macias | 146,479 | 1.29% |
| Mera Ii Llc\C | 133,372 | 1.18% |
| Oludare Odumosu | 131,766 | 1.16% |
| Citicorp Nominees Pty Limited | 128,727 | 1.13% |
| Mr Daniel Hexter and Mrs Shannon Hexter | 103,389 | 0.91% |
| Geers Egag Llc | 85,715 | 0.76% |
| Connie H Katz and Samuel P Katz | 78,063 | 0.69% |
